XW023X7 Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
Billable / valid for submission ICD10PCS Release FY2026-APR
Deleted from October 1, 2026. XW023X7 is not in FY2027. It stays valid through September 30, 2026.
Short description: Introduce Tixagev/Cilgavim in Muscle, Perc, New Tech 7
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| FY2026 | 2025-10-01 | 2026-03-31 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 | yes |
| FY2026-APR | 2026-04-01 | current | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 | yes |
Related codes in XW0
- XW0 New Technology, Anatomical Regions, Introduction
- XW00X27 Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
- XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10